- ProductsInvestment SuiteExclusiveFeatures
- PlatformTrading PlatformsFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketStocksIndicesMutual FundsIPO
- LearnStockshaalaResourceInvesting GuideEvents
- Partner
- Support
Products
Platform
Research
Market
Learn
Compare HDFC Pharma And Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.03 | 1.94 |
NAV | ₹15.78 | ₹36.53 |
Fund Started | 14 Sep 2023 | 25 Jun 2018 |
Fund Size | ₹1634.08 Cr | ₹4914.64 Cr |
Exit Load | Exit load of 1%, if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
4.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.03
1.94
NAV
₹15.78
₹36.53
Fund Started
14 Sep 2023
25 Jun 2018
Fund Size
₹1634.08 Cr
₹4914.64 Cr
Exit Load
Exit load of 1%, if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 27.74% | 20.01% |
3 Year | - | 22.27% |
5 Year | - | 25.41% |
1 Year
27.74%
20.01%
3 Year
-
22.27%
5 Year
-
25.41%
Holding Analysis
Equity | 97.27% | 98.28% |
Cash | 2.73% | 1.72% |
Equity
97.27%
98.28%
Cash
2.73%
1.72%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.84% |
Divi's Laboratories Ltd. | 8.55% |
Cipla Ltd. | 7.19% |
Lupin Ltd. | 5.43% |
Max Healthcare Institute Ltd. | 4.91% |
Krishna Institute of Medical Sciences Ltd | 4.04% |
Glenmark Pharmaceuticals Ltd. | 3.71% |
Torrent Pharmaceuticals Ltd. | 3.63% |
Aster DM Healthcare Ltd. | 3.54% |
Eris Lifesciences Ltd. | 3.31% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 13.50% |
Dr. Reddy's Laboratories Ltd. | 8.95% |
Cipla Ltd. | 8.85% |
Divi's Laboratories Ltd. | 6.71% |
Aurobindo Pharma Ltd. | 5.30% |
Lupin Ltd. | 4.73% |
Alkem Laboratories Ltd. | 4.42% |
Mankind Pharma Ltd. | 3.50% |
Gland Pharma Ltd. | 3.39% |
Zydus Lifesciences Ltd. | 3.10% |
Fund Manager
Name | Dhruv Muchhal | Dharmesh Kakkad |
Start Date | 14 Sep 2023 | 23 Feb 2021 |
Name
Dhruv Muchhal
Dharmesh Kakkad
Start Date
14 Sep 2023
23 Feb 2021
About Fund
Description | The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 14 Sep 2023 | 25 Jun 2018 |
Description
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
14 Sep 2023
25 Jun 2018